DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the calendar year (January through December) 2018. For audit purposes, please keep conflict of interest/financial records for three years after the conclusion of the award.

How to Use This Form:

- 1) Save the document on your drive.
- 2) Enter the Year (e.g. 2018), your Name, Title and Address in the appropriate fields.
- 3) Make sure you save your version on your drive.
- 4) Then Click on "File", click "Protect Document", in the drop-down menu click "Restrict Editing". In the column to the right at the bottom click "unprotect".
- 5) Click on the appropriate checkboxes.
- 6) Save your updated version on your drive
- 7) Send an email to DCRI Communications (DCRIExternalWebsite@dm.duke.edu) with your COI attached for posting on our DCRI website.

Editing the Document (Necessary only when you have to add companies not on the form):

- 1) Scroll down to the last page to the blank rows and enter the company name(s) on the company field(s).
- 2) Enter new information.
- 3) Click on the appropriate checkboxes on your new listing and save.
- Make sure you save your version on your drive.

Column Explanations:

- (1) Funding is provided for my effort in research grants or contracts for multi-center projects in which I serve as either the Chairman, Co-Chairman, Executive or Steering Committee member or I am involved as a DCRI faculty leader for specific aspects in a project. A check in this column denotes that I am involved in such a research contract. Payments for the work performed for these contracts are made to the University. A portion of my salary as a faculty member, representative of % effort on the project, is supported by these funds.
- (2) A research grant from this company supports the expenses associated with projects in the DUHS that are under my direction.
- (3) I provide educational activities or deliver occasional lectures that generate revenue from this company. All revenues from these activities are paid to the University. None of it is taken for personal income. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (4) I receive personal income outside of my University salary for consulting or other services (Including CME) from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (5) I receive personal income outside of my University salary for consulting or other non-CME services from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (6) I personally receive royalties in excess of \$5,000 per year from this company.
- (7) I, or an immediate member of my family, have equity (with shareholder voting privileges) in this company of either > \$5,000 or > 1%.

^{***}If you have no conflict to report please check the box at the end of the list.

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

Year:	2018
Name:	Stuart J. Knechtle, M.D.
Title:	Professor of Surgery
Address:	DUMC 3512, Durham, NC 27

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Company:	(1) A Research Grant or Contract from this Company Partially Supports My	Research Lectures for this Company			(4) Consulting or Other Services (Including CME) for this Company Generates Personal Income			(5) Consulting or Other non-CME Services for this Company Generates Personal Income			(6) I Receive Significant Personal Royalties from this	(7) I Have Equity in this Company		
	University Salary	Research Projects	<\$5K	\$5K- \$25K	>\$25K	<\$5K	\$5K- \$25K	>\$25K	<\$5K	\$5K- \$25K	>\$25K	Company	<\$5 K	>\$5K/1%
Abbott Laboratories														
Abbott Vascular Business (formerly Abbott Vascular Devices)														
AbbVie														
Abiomed														
Acceleron Pharma Inc														
Acerta Pharma														
ACIST Medical Systems, Inc														
AegisCN LLC														
Aires Pharmaceuticals														
Akili Interactive Labs														

Akros Pharmaceuticals							
Alexion							
Amgen, Inc							
Amylin Pharmaceuticals, Inc.							
ARCA biopharma							
Armis Biopharma							
Astellas Scientific and Medical Affairs Inc							
AstraZeneca							
Baseline Study LLC							
Basilea Pharmaceutica International Ltd							
Bayer AG							
Biosensors International Group Ltd							
Boehringer Ingleheim							
Boston Scientific Corporation							
Bristol Myers Squibb							Χ□
Cempra Pharmaceuticals, Inc.							
ContraFect Corporation							
CPC Clinical Research							

CryoLife Inc							
CSL Limited							
DAIICHI SANKYO COMPANY, LIMITED							
Datavant Inc							
David H Murdock Inst for Business and Culture							
Duke Clinical Research Institute							
Durata Therapeutics							
Eiger BioPharmaceutical s Inc							
Einstein HC Network Philadelphia							
Elesvier							
Eli Lilly & Company							
Eureka Therapeutics							
Evalve, Inc.							
Ferring Pharmaceuticals							
Filament BioSolutions							
Galectin Therapeutic							
Genentech							
General Electric Company							

Genetic Alliance							
Genzyme Corporation							
German AFNET							
Gilead							
GlaxoSmithKline plc							
Grifols							
HeartFlow							
Intarcia Therapeutics, Inc.							
Intra-Cellular Therapies Inc							
Ironwood Pharmaceuticals							
Janssen Pharmaceutica Products, L.P.							
Janssen Research and Development							
Janssen Scientific Affairs, LLC							
Japanese Org for Med Device Devlpt							
Johnson and Johnson Pharmaceutical Research and Development							
Kem Pharm Inc							
Ligand Pharmaceuticals							
Luitpold Pharmaceuticals, Inc.							

Lundbeck Pharmaceuticals							
Mallinckrodt							
Marinus Pharmaceuticals Inc							
Medtronic AVE							
Medtronic PLC							
Medtronic Vascular, Inc (formerly Medtronic AVE)							
Merck & Co, Inc.							
Mercy Health System							
Murdock							
MyoKardia Inc							
Novartis Pharmaceutical Company							
Olympus Corporation							
Oncternal Therapeutics							
OrbusNeich							
Otsuka America Pharmaceutical, Inc							
PATH							
PENTAX Medical							
Pfizer							X□
Purdue Pharma							
Reflexion Health							

Regeneron Pharmaceuticals, Inc							
ReNeuron							
Research Triangle Institute							
ResMed Corp							
Roche Diagnostics							
Roche Diagnostics Corp							
Roche Group							
Roche Labs							
Sanofi Genzyme							
Sanofi-Aventis							
Sanofi-Synthelabo							
Society of Thoracic Surgeons							
Summit							
Svelte Medical Systems Inc.							
Swedish Orphan Biovitrum AB							
Tacere Therapeutics							
Taiwanj Pharmaceuticals Company Ltd							
Takeda Pharmaceutical North America Inc							
TESARO Inc							
TEVA Pharmaceuticals Industries							

Theravance Biopharma							
Thrombosis Research Institute							
Ultragenyx Pharmaceuticals							
United Health Network							
Abbott Laboratories							

☐ No Conflicts to report

Column Explanations:

- (1) Funding is provided for my effort in research grants or contracts for multi-center projects in which I serve as either the Chairman, Co-Chairman, Executive or Steering Committee member or I am involved as a DCRI faculty leader for specific aspects in a project. A check in this column denotes that I am involved in such a research contract. Payments for the work performed for these contracts are made to the University. A portion of my salary as a faculty member, representative of % effort on the project, is supported by these funds.
- (2) A research grant from this company supports the expenses associated with projects in the DUHS that are under my direction.
- (3) I provide educational activities or deliver occasional lectures that generate revenue from this company. All revenues from these activities are paid to the University. None of it is taken for personal income. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (4) I receive personal income outside of my University salary for consulting or other services (Including CME) from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (5) I receive personal income outside of my University salary for consulting or other non-CME services from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (6) I personally receive royalties in excess of \$5,000 per year from this company.
- (7) I, or an immediate member of my family, have equity (with shareholder voting privileges) in this company of either > \$5,000 or > 1%.